Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PetVivo Holdings Inc. Warrant (PETVW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: PETVW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -9.09% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.85 | 52 Weeks Range 0.03 - 0.10 | Updated Date 06/22/2025 |
52 Weeks Range 0.03 - 0.10 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -301.45% |
Management Effectiveness
Return on Assets (TTM) -159.92% | Return on Equity (TTM) -8616.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16029244 |
Shares Outstanding - | Shares Floating 16029244 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
PetVivo Holdings Inc. Warrant
Company Overview
History and Background
PetVivo Holdings, Inc. is a biomedical device company focused on the development, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. They were founded in 2010. The PetVivo warrant gives the holder the right to purchase shares of PetVivo Holdings, Inc. common stock at a specified price.
Core Business Areas
- Therapeutics: Development and commercialization of veterinary medical devices and therapeutics.
Leadership and Structure
The leadership team comprises experienced professionals in veterinary medicine and business development. The organizational structure is typical of a small, publicly traded biomedical company.
Top Products and Market Share
Key Offerings
- Spryng with OsteoCushion Technology: A veterinarian-administered, intraarticular injection for the treatment of lameness and other joint-related afflictions in dogs, horses and cats. There is no public data on specific market share or revenue. Competitors include other injectable joint treatments and supplements.
Market Dynamics
Industry Overview
The veterinary medicine market is growing due to increased pet ownership and a willingness to spend more on pet health. The market is competitive, with established players and emerging companies.
Positioning
PetVivo is a smaller player aiming to disrupt the market with its innovative Spryng product. Their competitive advantage lies in their novel OsteoCushion Technology.
Total Addressable Market (TAM)
The global veterinary medicine market is projected to reach billions of dollars. PetVivo's TAM is focused on the osteoarthritis treatment segment within this broader market, estimated to be hundreds of millions. They are positioned to capture a portion of this segment with their innovative technology.
Upturn SWOT Analysis
Strengths
- Innovative OsteoCushion Technology
- Targeted product for osteoarthritis in animals
- Potential for licensing agreements
Weaknesses
- Limited financial resources
- Small market share
- Dependence on single product (Spryng)
Opportunities
- Expansion into new animal species (e.g., cats, horses)
- Strategic partnerships with veterinary clinics
- Licensing agreements with larger pharmaceutical companies
Threats
- Competition from established veterinary pharmaceutical companies
- Regulatory hurdles for new veterinary products
- Potential for product liability claims
Competitors and Market Share
Key Competitors
- ZOET
- MRK
- ELAN
Competitive Landscape
PetVivo is a small player facing intense competition from larger, more established veterinary pharmaceutical companies. Their competitive advantage lies in their innovative OsteoCushion Technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow due to product development and limited commercialization.
Future Projections: Future growth depends on successful commercialization of Spryng and potential licensing agreements. Analyst estimates are not readily available for smaller companies like PetVivo.
Recent Initiatives: Focus on expanding distribution network and increasing product awareness among veterinarians.
Summary
PetVivo Holdings, Inc. is a small biomedical company with an innovative product, Spryng, for treating osteoarthritis in animals. The company faces significant financial challenges and intense competition from larger players. Its success depends on successful commercialization, strategic partnerships, and navigating regulatory hurdles. They have a long way to go to improve shareholder returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Veterinary Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share and revenue data may be estimates and are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PetVivo Holdings Inc. Warrant
Exchange NASDAQ | Headquaters Edina, MN, United States | ||
IPO Launch date 2021-08-11 | CEO, President & Director Mr. John Lai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 20 | Website https://www.petvivo.com |
Full time employees 20 | Website https://www.petvivo.com | ||
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Edina, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.